Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Menarini
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MEN1703 (SEL24) is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile, which is investigated for the treatment of diffuse large B-cell lymphoma.
Brand Name : MEN1703
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2023
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Menarini
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ryvu Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in the DIAMOND-01 trial as a single agent for the treatment of patients with relapsed/refractory AML.
Brand Name : SEL24
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2021
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ryvu Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the dose escalation part of DIAMOND-01 trial, SEL24(MEN1703) demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of anti-leukemic activity in a single agent setting.
Brand Name : SEL24
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2021
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Menarini
Deal Size : Not Applicable
Deal Type : Not Applicable
Ryvu Begins Patient Dosing in Europe for Phase I/II DIAMOND-01 Trial of SEL24/MEN1703 to Treat AML
Details : First patient has been treated in Europe for the cohort expansion part of Phase II DIAMOND-01 clinical trial investigating SEL24/MEN1703, a first-in-class, oral dual PIM/FLT3 inhibitor, as single agent in Acute Myeloid Leukemia (AML).
Brand Name : SEL24
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2020
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Menarini
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The poster concerning SEL24/MEN1703, is the first report on the successful completion of Phase I clinical study of SEL24/MEN1703 in Acute Myeloid Leukemia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 14, 2020
Lead Product(s) : MEN1703
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?